ABRYSVOᴹᴰ now approved for adults aged 18–59

A Major Advance Against RSV

The AES Vaccination Center is pleased to announce news that will change the prevention of respiratory syncytial virus (RSV) in Canada.

According to official information published by Pfizer Canada, Health Canada has approved a new indication for the ABRYSVOᴹᴰ vaccine: it can now be administered to adults aged 18 to 59 with an increased risk of lower respiratory tract disease (LRTD) caused by RSV.

This update marks a significant step forward in protecting an adult population that, until now, had no vaccine option.

Why is this approval important?

RSV is a highly contagious respiratory virus that affects people of all ages. While it often causes cold-like symptoms, it can also lead to serious complications, especially in:

Until now, at-risk adults aged 18 to 59 had no vaccine protection against RSV. With this new indication, a major unmet need is finally addressed!

A Single Vaccine for Two Age Groups

ABRYSVOᴹᴰ is currently the only vaccine:

This dual indication makes it an essential tool for protecting adults, as well as infants.

What This Means for the At-Risk Population

Although RSV is primarily recognized for its impact on infants and the elderly, it can also cause serious complications in certain adults with specific health conditions.

The expanded indication for ABRYSVO therefore represents a significant advance: for the first time, a vaccine can protect adults aged 18 to 59 with an increased risk of developing an RSV-related respiratory infection.

This update demonstrates a clear commitment to improving prevention and making protection accessible to more people throughout different life stages.

What This Means for Our Patients

Thanks to this new authorization, the AES Vaccination Center can now offer additional protection to at-risk adults aged 18 to 59. Our team of specialized nurses is available to answer your questions, assess your situation, and guide you through vaccine recommendations.

Public Reimbursement in Several Provinces: What This Means for Public Health

The expanded approval of ABRYSVOᴹᴰ comes with another significant development: for the 2025-2026 season, the vaccine is now reimbursed by the public health system in several Canadian provinces, following a national tender.

This reimbursement demonstrates a clear commitment from provincial governments to:

Some provinces, like Ontario, go even further by offering ABRYSVOᴹᴰ not only to older adults but also to pregnant individuals — which helps protect infants from birth through maternal immunization.

For individuals not eligible for public reimbursement, it is important to note that the vaccine may also be covered by certain private insurance plans.

Would you like to learn more about ABRYSVOᴹᴰ or check if this vaccine is recommended for you?

Whether it’s to understand if this vaccine is recommended for your situation, get personalized advice, or simply ask your questions, our team is here to guide you. Each person has a unique health profile, and we are here to offer you tailored, clear, and reassuring support.

Do not hesitate to contact us today to speak with our professionals, get more information, or schedule an appointment. We will be happy to help you make an informed choice for your health.